EPO Patent Bulletin - Peptides (C07K)

EP4146277A1 - Avian Antibodies Reduce Viral Disease Transmission

The European Patent Office granted Patent EP4146277A1 to Camas Incorporated on April 8, 2026, covering compositions and methods for using avian antibodies to reduce viral disease transmission. The patent names nine inventors and is classified under IPC categories A61K 39/42, A61P 11/00, A61P 31/12, and C07K 16/08. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, and Spain.

Fate Therapeutics iPSC Effector Cells for Immunotherapy Patent EP4168538A1

The European Patent Office published patent application EP4168538A1 for Fate Therapeutics, Inc., covering methods of combining iPSC-derived effector cell types for immunotherapy use. The patent includes claims related to cell therapy compositions, cytokine combinations, and therapeutic applications for cancer treatment. The patent designation covers 31 European member states.

ENPP1 Antibody Inhibitors - University of California

The European Patent Office published application EP4146706A1 for ENPP1 antibody inhibitors filed by The Regents of the University of California. The application claims anti-ENPP1 antibodies for therapeutic use, classified under IPC C07K 16/40, A61P 9/10, A61K 39/395, and C12N 15/63. The application designates all relevant European member states including AT, BE, DE, FR, GB, IT, NL, ES, PL, and 25 others.

EP4200339A2 - Compositions and Methods Related to Receptor Pairings

European Patent Office granted Patent EP4200339A2 to Synthekine, Inc. covering compositions and methods related to receptor pairings. The patent application, filed with IPC classifications C07K 16/28, C07K 14/715, and C07K 14/705, lists inventors KASTELEIN Robert, LUPARDUS Patrick J., and ROKKAM Deepti. The patent is designated across all European member states.

Long Acting GLP-1 Receptor Agonists and Methods of Use

The European Patent Office published patent application EP4263587A1 for long-acting GLP-1 receptor agonists filed by I2O Therapeutics, Inc. The patent covers glucagon-like polypeptide-1 receptor agonist compositions and methods of use for treating metabolic disorders including obesity, hyperlipidemia, and diabetes. The patent is directed to peptide compounds classified under C07K 14/605 with designated protection across 31 European member states.

Modified B Cells and Methods of Use Thereof - EP4203978A1

The European Patent Office published patent application EP4203978A1 for Modified B Cells and Methods of Use Thereof, filed by Walking Fish Therapeutics, Inc. The patent covers engineered B cells for therapeutic applications, including cancer treatment indications (A61P 35/00). The application contains 18 IPC classifications spanning peptides, immunology, gene therapy vectors, and therapeutic preparations.

Tetravalent Bispecific Antibody, Preparation Method Therefor, and Use Thereof

The European Patent Office published patent application EP3967711A1 for a tetravalent bispecific antibody filed by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. The application covers the antibody's preparation method and therapeutic uses. The A1 publication includes a European search report and designates 32 member states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

IL10 Receptor Binding Molecules and Methods of Use - EP4192880A2

The European Patent Office published application EP4192880A2, a patent for IL10 receptor binding molecules and methods of use, filed by Synthekine, Inc. The patent covers C07K peptide-based compounds under classifications C07K 16/28, C07K 14/715, and C07K 14/705. The application designates all EU member states and participating EPC contracting states including CH, LI, NO, TR, and MC.

Orthogonal Mutations for Heterodimerization - Invenra Inc.

EPO published patent application EP4259194A1 titled 'Orthogonal Mutations for Heterodimerization' filed by Invenra Inc. The invention relates to methods for creating orthogonal mutation pairs to facilitate controlled heterodimerization of proteins, with applications in bispecific antibody development and therapeutic protein engineering. The application covers 47 designated EU member and extension states including Germany, France, UK, Italy, Spain, and other EPC contracting states.